McKesson Corp Files 8-K on Financials & Operations
Ticker: MCK · Form: 8-K · Filed: Sep 18, 2025 · CIK: 927653
| Field | Detail |
|---|---|
| Company | Mckesson CORP (MCK) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
Related Tickers: MCK
TL;DR
McKesson dropped an 8-K detailing financials and operations - check it for the latest numbers.
AI Summary
McKesson Corporation filed an 8-K on September 18, 2025, reporting on its results of operations and financial condition, along with other events and financial statements. The filing indicates the company's fiscal year ends on March 31st and provides details on its corporate structure and previous name changes.
Why It Matters
This filing provides an update on McKesson's financial performance and operational events, which is crucial for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, not indicating any immediate or significant new risks.
Key Players & Entities
- MCKESSON CORP (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 94-3207296 (tax_id) — EIN
- September 18, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on McKesson Corporation's Results of Operations and Financial Condition, as well as other events and financial statements.
When was this 8-K report filed?
This 8-K report was filed on September 18, 2025.
What is McKesson Corporation's state of incorporation?
McKesson Corporation is incorporated in Delaware.
What is McKesson Corporation's Employer Identification Number (EIN)?
McKesson Corporation's EIN is 94-3207296.
What is McKesson Corporation's fiscal year end?
McKesson Corporation's fiscal year ends on March 31st.
Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2025-09-18 08:00:41
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value MCK New York Stock Exchange
Filing Documents
- mck-20250918.htm (8-K) — 39KB
- mck_ex991resegementation.htm (EX-99.1) — 236KB
- mck-20250918_g1.jpg (GRAPHIC) — 11KB
- 0000927653-25-000121.txt ( ) — 487KB
- mck-20250918.xsd (EX-101.SCH) — 3KB
- mck-20250918_def.xml (EX-101.DEF) — 16KB
- mck-20250918_lab.xml (EX-101.LAB) — 30KB
- mck-20250918_pre.xml (EX-101.PRE) — 17KB
- mck-20250918_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. The information set forth in Item 8.01 is incorporated herein by reference.
01
Item 8.01 Other Events Commencing in the second quarter of fiscal 2026, McKesson Corporation (the "Company," "McKesson," "we," "our," and other similar pronouns) will report financial results across four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. Our Norwegian operations will be included in Other. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. These segment changes reflect how our Chief Executive Officer, who is our chief operating decision maker, allocates resources and assesses performance beginning in the second quarter of fiscal 2026. The segment changes did not impact our previously issued consolidated financial statements or our historical earnings per diluted share. Additional information regarding our reportable segments is as follows: North American Pharmaceutical : A newly defined reportable segment combining McKesson's scaled wholesale drug distribution businesses in the United States and Canada. It delivers best-in-class distribution services to a broad customer base, including retail and community pharmacies, and institutional healthcare providers. Oncology & Multispecialty : A newly defined reportable segment that includes a portfolio of integrated solutions across oncology and multispecialty providers and solutions. The segment includes specialty provider solutions, including distribution-related capabilities, such as specialty drug distribution and group purchasing organizations; and Practice management services supporting the largest physician-led, community-based oncology networks. The segment also includes other multispecialty providers, including retina and ophthalmology, and offers clinical trial services, specialty pharmacy solutions, and access to cutting-edge research, along with innovation through
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibit 99.1 is filed with this Current Report on Form 8-K . Exhibit No. Description 99.1 Supplemental Historical Financial Information by New Reportable Segment For Fiscal Quarters Ended June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, and June 30, 2025, and for the fiscal years ended March 31, 2025 and 2024 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2025 McKesson Corporation By: /s/ Britt J. Vitalone Britt J. Vitalone Executive Vice President and Chief Financial Officer